Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

Guggenheim reaffirmed a buy rating on Pfizer with a $36 price target, implying 38% upside from the recent share price of about $26. The report points to Pfizer’s 96-drug pipeline, including 31 late-stage assets, and highlights potential upside from the Mevpro-1 phase 3 trial and acquired GLP-1 developer Metsera. Pfizer’s 6.7% dividend yield provides additional support while investors wait for pipeline catalysts.

Analysis

Pfizer’s setup is less about a near-term rerating and more about a long-duration de-risking of a classic patent-cliff story. The key second-order effect is that a credible mid/late-stage pipeline can compress the market’s implied terminal decline rate, which matters more here than any single readout; if investors start underwriting even one or two durable post-LOE offsets, the stock can move from a value trap multiple to a cash-flow compounder multiple. That creates upside not just in the equity, but in the company’s cost of capital, giving management more optionality on buybacks, licensing, and bolt-on M&A.

The market is likely underappreciating how asymmetric binary readouts become when the stock already screens as a high-yield defensive name. With a high starting dividend, the equity behaves like a funded call option on pipeline success: downside is cushioned unless the balance sheet or payout becomes contested, while upside can re-rate quickly if late-stage oncology or obesity data are credible. The real risk is not one failed asset, but a cluster of disappointments that forces investors to focus on declining ex-patent cash flows and eventually price the dividend as a trap rather than support.

Competitively, a successful obesity or oncology asset would not just help Pfizer; it would pressure peers with similar pipelines to spend more aggressively, raising industrywide R&D intensity and M&A premiums. Conversely, if Pfizer is forced to chase growth externally, acquisition discipline becomes the key variable — overpaying for assets in hot therapeutic areas would destroy the very cash-return profile currently supporting the stock. The market appears to be paying for yield today and for pipeline tomorrow, which is exactly where sentiment can swing most violently on a single data event.

Key Decisions for Investors

• Long PFE into the next 6-12 month clinical-data window, with a target of a partial rerating if late-stage readouts remain constructive; risk/reward is favorable because the dividend provides carry while waiting, but size modestly because binary trial outcomes can gap the stock 10-15%.
• Buy PFE January 2027 upside calls or call spreads to express the asymmetric pipeline optionality; this is cleaner than common stock if the goal is to monetize a successful readout without taking full dividend-yield exposure.
• Pair trade: long PFE / short a higher-multiple large-cap pharma with similar pipeline dependence but weaker cash return support, to isolate the valuation impact of yield plus de-risking; hold through the next major phase 3 catalyst.
• Use any rally into trial optimism to sell upside against long stock, because the market may overpay for binary optimism before results; this is attractive if implied volatility remains cheap relative to the event risk.
• Do not chase if the stock moves sharply higher on headline pipeline enthusiasm alone; wait for confirmation from data, since the most durable rerating comes only when investors gain confidence that the post-patent cash-flow bridge is real.